BinoNews
Topic

#ascletis

2 stories

Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne
Stocks·

Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne

Sagimet Biosciences, the strategic partner of Ascletis Pharma, has successfully dosed the first patient in a pivotal Phase III U.S. clinical trial evaluating denifanstat for moderate to severe acne. This milestone advances the therapeutic candidate closer to potential commercialization.

2.2K8812
Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity
Stocks·

Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity

Ascletis reported positive preclinical data for its once-weekly oral peptide pipeline targeting obesity and metabolic disorders. The comprehensive portfolio covers four validated therapeutic targets with potential first-in-class fixed-dose combinations.

2K1145